MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 510319 | Name: Vidofludimus
Featured New

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Vidofludimus, also known as 4SC 101 or SC12267, is a novel orally active and potent DHODH inhibitor. In vitro, 4SC-101 is a potent inhibitor of human DHODH, inhibits lymphocyte proliferation, and uniquely blocks phytohemagglutinin-stimulated IL-17 production by lymphocytes. In vivo, oral administration of 4SC-101 effectively improved both chronic DSS and acute TNBS colitis in mice. 4SC-101 may have potential for the treatment of intestinal inflammation. Dihydroorotate dehydrogenase (DHODH) is a key enzyme involved in pyrimidine biosynthesis. DHODH is a known target for the treatment of autoimmune diseases.

Chemical Structure

Vidofludimus
Vidofludimus
CAS#717824-30-1 (free acid)

Theoretical Analysis

MedKoo Cat#: 510319

Name: Vidofludimus

CAS#: 717824-30-1 (free acid)

Chemical Formula: C20H18FNO4

Exact Mass: 355.1220

Molecular Weight: 355.36

Elemental Analysis: C, 67.60; H, 5.11; F, 5.35; N, 3.94; O, 18.01

Price and Availability

Size Price Availability Quantity
10mg USD 90.00 Ready to ship
25mg USD 195.00 Ready to ship
50mg USD 350.00 Ready to ship
100mg USD 630.00 Ready to ship
200mg USD 1,130.00 Ready to ship
500mg USD 2,450.00 2 weeks
1g USD 3,250.00 2 weeks
2g USD 5,850.00 2 weeks
Show More
Bulk Inquiry
Buy Now
Add to Cart
Related CAS #
717824-30-1 (free acid) 1354012-90-0 (calcium) 1354013-27-6 (potassium) 2245772-26-1 (sodium) 1354023-23-6 (tris)
Synonym
Vidofludimus; 4SC 101; 4SC-101; 4SC101; SC12267; SC-12267; SC 12267; IMU-838; IMU838; IMU 838; IM90838; IM 90838; IM-90838;
IUPAC/Chemical Name
2-((3-fluoro-3'-methoxy-[1,1'-biphenyl]-4-yl)carbamoyl)cyclopent-1-enecarboxylic acid
InChi Key
XPRDUGXOWVXZLL-UHFFFAOYSA-N
InChi Code
InChI=1S/C20H18FNO4/c1-26-14-5-2-4-12(10-14)13-8-9-18(17(21)11-13)22-19(23)15-6-3-7-16(15)20(24)25/h2,4-5,8-11H,3,6-7H2,1H3,(H,22,23)(H,24,25)
SMILES Code
COC1=CC=CC(C2=CC(F)=C(NC(C3=C(C(O)=O)CCC3)=O)C=C2)=C1
Appearance
Light yellow solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO, not in water
Shelf Life
>5 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info
        
Biological target:
Vidofludimus(4SC-101; SC12267) is a novel immunosuppressive drug that inhibits DHODH and inhibits IL-17 in vitro.
In vitro activity:
The antiviral activity of IMU-838 was determined by RT-qPCR using infectious supernatants of SARS-CoV-2-infected Vero cells. Cells were used for infection with SARS-CoV-2 at an MOI of 0.0002 for 2–3 days, before supernatants were collected and subjected to the determination of extracellular viral load by RT-qPCR. In all cases of the slightly modified settings in replicates 1–3, the EC50 values of IMU-838 remained in the low micromolar range (6.0 ± 5.0 µM to 10.0 ± 9.0 µM), so that a mean of 7.6 ± 5.8 µM was calculated (Figure 3A). This result was further illustrated by the use of the remaining cell layers for assessing the drug-mediated inhibition of intracellular viral load by an immunostaining of cell layers in the in-cell ELISA (Figure 3B). This finding was supported by the in-cell IF data described above, indicating the IMU-838-mediated inhibition of viral spike protein and RNA production, with a concentration-dependent reduction of both signals, as compared to the DMSO infection-positive and mock-infected negative controls (Figure 1C). These data indicated a pronounced in vitro anti-SARS-CoV-2 activity of the developmental drug IMU-838. Reference: Viruses. 2020 Dec; 12(12): 1394. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7762174/
In vivo activity:
Female MRl lpr/lpr mice were treated with 4SC-101, CYC, or vehicle from 12 to 22 weeks of age because at 12 weeks of age MRLlpr/lpr mice show first signs of proliferative immune complex glomerulonephritis and proteinuria. After 10 weeks of treatment, vehicle-treated MRLlpr/lpr mice showed diffuse proliferative immune complex glomerulonephritis characterized by glomerular IgG deposits, mesangioproliferative glomerulonephritis, considerable tubular atrophy, and interstitial fibrosis (Figure 4A). 4SC-101 reduced the glomerular IgG deposits and improved the lupus-like immune complex glomerulonephritis in female MRLlpr/lpr mice in a dose dependent manner (Figure 4A). The chronicity score, a composite score of glomerular and interstitial scarring, was significant for the 300 mg/kg 4SC-101 group. 300 mg/kg 4SC-101 reduced renal macrophage and T cell infiltrates (Figure 4C). 4SC-101 treatment was also associated with an increase of GFR (Glomerular filtration rate) and a decrease of albuminuria in a dose-dependent manner (Figure 5, A and B). It is concluded that the dose-dependent impact of 4SC-101 on systemic autoimmunity translates into antiinflammatory effects on lupus nephritis and improvement of renal dysfunction in MRLlpr/lpr mice. Reference: Am J Pathol. 2010 Jun; 176(6): 2840–2847. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2877845/
Solvent mg/mL mM
Solubility
DMSO 57.0 160.40
Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.

Preparing Stock Solutions

The following data is based on the product molecular weight 355.36 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
1. Kulkarni OP, Sayyed SG, Kantner C, Ryu M, Schnurr M, Sárdy M, Leban J, Jankowsky R, Ammendola A, Doblhofer R, Anders HJ. 4SC-101, a novel small molecule dihydroorotate dehydrogenase inhibitor, suppresses systemic lupus erythematosus in MRL(Fas)lpr mice. Am J Pathol. 2010 Jun;176(6):2840-7. doi: 10.2353/ajpath.2010.091227. Epub 2010 Apr 22. PMID: 20413687; PMCID: PMC2877845. 2. Hahn F, Wangen C, Häge S, Peter AS, Dobler G, Hurst B, Julander J, Fuchs J, Ruzsics Z, Überla K, Jäck HM, Ptak R, Muehler A, Gröppel M, Vitt D, Peelen E, Kohlhof H, Marschall M. IMU-838, a Developmental DHODH Inhibitor in Phase II for Autoimmune Disease, Shows Anti-SARS-CoV-2 and Broad-Spectrum Antiviral Efficacy In Vitro. Viruses. 2020 Dec 5;12(12):1394. doi: 10.3390/v12121394. PMID: 33291455; PMCID: PMC7762174.
In vitro protocol:
1. Kulkarni OP, Sayyed SG, Kantner C, Ryu M, Schnurr M, Sárdy M, Leban J, Jankowsky R, Ammendola A, Doblhofer R, Anders HJ. 4SC-101, a novel small molecule dihydroorotate dehydrogenase inhibitor, suppresses systemic lupus erythematosus in MRL(Fas)lpr mice. Am J Pathol. 2010 Jun;176(6):2840-7. doi: 10.2353/ajpath.2010.091227. Epub 2010 Apr 22. PMID: 20413687; PMCID: PMC2877845. 2. Hahn F, Wangen C, Häge S, Peter AS, Dobler G, Hurst B, Julander J, Fuchs J, Ruzsics Z, Überla K, Jäck HM, Ptak R, Muehler A, Gröppel M, Vitt D, Peelen E, Kohlhof H, Marschall M. IMU-838, a Developmental DHODH Inhibitor in Phase II for Autoimmune Disease, Shows Anti-SARS-CoV-2 and Broad-Spectrum Antiviral Efficacy In Vitro. Viruses. 2020 Dec 5;12(12):1394. doi: 10.3390/v12121394. PMID: 33291455; PMCID: PMC7762174.
In vivo protocol:
1. Kulkarni OP, Sayyed SG, Kantner C, Ryu M, Schnurr M, Sárdy M, Leban J, Jankowsky R, Ammendola A, Doblhofer R, Anders HJ. 4SC-101, a novel small molecule dihydroorotate dehydrogenase inhibitor, suppresses systemic lupus erythematosus in MRL(Fas)lpr mice. Am J Pathol. 2010 Jun;176(6):2840-7. doi: 10.2353/ajpath.2010.091227. Epub 2010 Apr 22. PMID: 20413687; PMCID: PMC2877845
1: D'Haens G, Stardelova KG, Sadiku E, Kizlova N, Skybalo S, Shehovtsova Y, Abramescu M, Vitt D, Kohlhof H, Muehler A. Vidofludimus Calcium in Patients with Moderate-to-Severe Ulcerative Colitis: A Randomized, Placebo-Controlled, Phase 2 Trial. Clin Transl Gastroenterol. 2025 Jan 10. doi: 10.14309/ctg.0000000000000813. Epub ahead of print. PMID: 39791563. 2: Yang Y, Gao Y, Zhang L, Liu X, Sun Y, Bai J, Jiang P. Correction: Vidofludimus inhibits porcine reproductive and respiratory syndrome virus infection by targeting dihydroorotate dehydrogenase. Vet Res. 2024 Dec 27;55(1):173. doi: 10.1186/s13567-024-01447-y. Erratum for: Vet Res. 2023 Dec 20;54(1):124. doi: 10.1186/s13567-023-01251-0. PMID: 39731128; PMCID: PMC11681666. 3: Gege C, Hahn F, Wangen C, Häge S, Herrmann A, Uhlig N, Eberlein V, Issmail L, Klopfleisch R, Grunwald T, Marschall M, Kohlhof H, Vitt D. Synthesis and Characterization of DHODH Inhibitors Based on the Vidofludimus Scaffold with Pronounced Anti-SARS-CoV-2 Activity. ChemMedChem. 2024 Oct 1;19(19):e202400292. doi: 10.1002/cmdc.202400292. Epub 2024 Aug 6. PMID: 38887198. 4: Fox RJ, Wiendl H, Wolf C, De Stefano N, Sellner J, Gryb V, Rejdak K, Bozhinov PS, Vitt D, Kohlhof H, Slizgi J, Ondrus M, Sciacca V, Muehler AR; EMPhASIS investigators. Safety and Dose-Response of Vidofludimus Calcium in Relapsing Multiple Sclerosis: Extended Results of a Placebo-Controlled Phase 2 Trial. Neurol Neuroimmunol Neuroinflamm. 2024 May;11(3):e200208. doi: 10.1212/NXI.0000000000200208. Epub 2024 Apr 25. PMID: 38662979; PMCID: PMC11087024. 5: Sriwastava S, Elkhooly M, Amatya S, Shrestha K, Kagzi Y, Bhatia D, Gupta R, Jaiswal S, Lisak RP. Recent advances in the treatment of primary and secondary progressive Multiple Sclerosis. J Neuroimmunol. 2024 May 15;390:578315. doi: 10.1016/j.jneuroim.2024.578315. Epub 2024 Feb 17. PMID: 38554666. 6: Li J, Takeda M, Imahatakenaka M, Ikeda M. Identification of dihydroorotate dehydrogenase inhibitor, vidofludimus, as a potent and novel inhibitor for influenza virus. J Med Virol. 2024 Jan;96(1):e29372. doi: 10.1002/jmv.29372. PMID: 38235544. 7: Sotorilli GE, Gravina HD, de Carvalho AC, Shimizu JF, Fontoura MA, Melo- Hanchuk TD, Cordeiro AT, Marques RE. Phenotypical Screening of an MMV Open Box Library and Identification of Compounds with Antiviral Activity against St. Louis Encephalitis Virus. Viruses. 2023 Dec 13;15(12):2416. doi: 10.3390/v15122416. PMID: 38140657; PMCID: PMC10747599. 8: Yang Y, Gao Y, Zhang L, Liu X, Sun Y, Bai J, Jiang P. Vidofludimus inhibits porcine reproductive and respiratory syndrome virus infection by targeting dihydroorotate dehydrogenase. Vet Res. 2023 Dec 20;54(1):124. doi: 10.1186/s13567-023-01251-0. Erratum in: Vet Res. 2024 Dec 27;55(1):173. doi: 10.1186/s13567-024-01447-y. PMID: 38124181; PMCID: PMC10731701. 9: Guo H, Liu D, Liu K, Hou Y, Li C, Li Q, Ding X, Verstegen MMA, Zhang J, Wang L, Ding Y, Tang R, Pan X, Zheng K, van der Laan LJW, Pan Q, Wang W. Drug repurposing screen identifies vidofludimus calcium and pyrazofurin as novel chemical entities for the development of hepatitis E interventions. Virol Sin. 2024 Feb;39(1):123-133. doi: 10.1016/j.virs.2023.11.006. Epub 2023 Nov 19. PMID: 37984761; PMCID: PMC10877426. 10: Zhou X, Gou K, Xu J, Jian L, Luo Y, Li C, Guan X, Qiu J, Zou J, Zhang Y, Zhong X, Zeng T, Zhou Y, Xiao Y, Yang X, Chen W, Gao P, Liu C, Zhou Y, Tao L, Liu X, Cen X, Chen Q, Sun Q, Luo Y, Zhao Y. Discovery and Optimization of Novel hDHODH Inhibitors for the Treatment of Inflammatory Bowel Disease. J Med Chem. 2023 Nov 9;66(21):14755-14786. doi: 10.1021/acs.jmedchem.3c01365. Epub 2023 Oct 23. PMID: 37870434. 11: Vietor J, Gege C, Stiller T, Busch R, Schallmayer E, Kohlhof H, Höfner G, Pabel J, Marschner JA, Merk D. Development of a Potent Nurr1 Agonist Tool for In Vivo Applications. J Med Chem. 2023 May 11;66(9):6391-6402. doi: 10.1021/acs.jmedchem.3c00415. Epub 2023 Apr 26. PMID: 37127285; PMCID: PMC10184128. 12: Li X, Zhao D, Zhao X, Cheng P, Li F, Sun J, Li Y, Bai J, Zhang X. The activity and mechanism of vidofludimus as a potent enzyme inhibitor against NDM-1-positive E. coli. Eur J Med Chem. 2023 Mar 15;250:115225. doi: 10.1016/j.ejmech.2023.115225. Epub 2023 Feb 28. PMID: 36870273. 13: James JR, Curd J, Ashworth JC, Abuhantash M, Grundy M, Seedhouse CH, Arkill KP, Wright AJ, Merry CLR, Thompson A. Hydrogel-Based Pre-Clinical Evaluation of Repurposed FDA-Approved Drugs for AML. Int J Mol Sci. 2023 Feb 20;24(4):4235. doi: 10.3390/ijms24044235. PMID: 36835644; PMCID: PMC9966469. 14: Hackler J, Demircan K, Chillon TS, Sun Q, Geisler N, Schupp M, Renko K, Schomburg L. High throughput drug screening identifies resveratrol as suppressor of hepatic SELENOP expression. Redox Biol. 2023 Feb;59:102592. doi: 10.1016/j.redox.2022.102592. Epub 2022 Dec 26. PMID: 36586222; PMCID: PMC9816962. 15: Sharma K, Berry L, Vryonis E, Ali A, Lara B, Noufaily A, Parsons N, Bradley C, Haley B, Tabuso M, Arasaradnam RP. Prospective, randomised, parallel-group, open-label study to evaluate the effectiveness and safety of IMU-838, in combination with oseltamivir, in adults with COVID-19: the IONIC trial protocol. BMJ Open. 2022 Nov 17;12(11):e055205. doi: 10.1136/bmjopen-2021-055205. PMID: 36396307; PMCID: PMC9676417. 16: Vehreschild MJGT, Atanasov P, Yurko K, Oancea C, Popov G, Smesnoi V, Placinta G, Kohlhof H, Vitt D, Peelen E, Mihajlović J, Muehler AR. Safety and Efficacy of Vidofludimus Calcium in Patients Hospitalized with COVID-19: A Double-Blind, Randomized, Placebo-Controlled, Phase 2 Trial. Infect Dis Ther. 2022 Dec;11(6):2159-2176. doi: 10.1007/s40121-022-00690-0. Epub 2022 Oct 15. PMID: 36242741; PMCID: PMC9568890. 17: Peterson S, Jalil A, Beard K, Kakara M, Sriwastava S. Updates on efficacy and safety outcomes of new and emerging disease modifying therapies and stem cell therapy for Multiple Sclerosis: A review. Mult Scler Relat Disord. 2022 Dec;68:104125. doi: 10.1016/j.msard.2022.104125. Epub 2022 Aug 31. PMID: 36057173. 18: Fox RJ, Wiendl H, Wolf C, De Stefano N, Sellner J, Gryb V, Rejdak K, Bozhinov PS, Tomakh N, Skrypchenko I, Muehler AR. A double-blind, randomized, placebo-controlled phase 2 trial evaluating the selective dihydroorotate dehydrogenase inhibitor vidofludimus calcium in relapsing-remitting multiple sclerosis. Ann Clin Transl Neurol. 2022 Jul;9(7):977-987. doi: 10.1002/acn3.51574. Epub 2022 Jun 14. PMID: 35698927; PMCID: PMC9268865. 19: Tang H, Liu Y, Ren R, Liu Y, He Y, Qi Z, Peng H, Zhao P. Identification of clinical candidates against West Nile virus by activity screening in vitro and effect evaluation in vivo. J Med Virol. 2022 Oct;94(10):4918-4925. doi: 10.1002/jmv.27891. Epub 2022 Jun 18. PMID: 35644833. 20: Rossi E, Leccese G, Baldelli V, Bibi A, Scalone E, Camilloni C, Paroni M, Landini P. Inactivation of the Pyrimidine Biosynthesis pyrD Gene Negatively Affects Biofilm Formation and Virulence Determinants in the Crohn's Disease-Associated Adherent Invasive Escherichia coli LF82 Strain. Microorganisms. 2022 Feb 28;10(3):537. doi: 10.3390/microorganisms10030537. PMID: 35336113; PMCID: PMC8956108.